Soprobec 200 mcg inhaler information
Click to view latest direct healthcare professional communication (DHPC).
Intended for UK healthcare professionals only.
The extra ‘L’ is for Low cost.
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to medical_information@glenmarkpharma.com
or call 0800 458 0383.
(Long-Acting Muscarinic
Antagonists) are effective
bronchodilators that help
COPD patients breathe
(and live) more easily.1
(Low-cost Long-Acting
Muscarinic Antagonists) do
exactly the same but cost
less than other LAMAs.2,3
is a once-daily therapy that offers
the efficacy and safety associated
with tiotropium4 at one of the
lowest costs,2,3 making it a true
LLAMA for COPD.
Tiogiva contains tiotropium bromide in an inhalation powder. It comes in clear hard capsules,
with a metered dose of 18 mcg tiotropium per capsule and delivered dose of 10 mcg.5
Maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD) in adults only.
The recommended dosage is one capsule once daily, inhaled using the Tiogiva capsule inhaler, at the same time of day. To get a full daily dose, the patient should inhale a second time from the same capsule.
Tiogiva is like Spiriva®
Same active substance and dosage5,6
Bioequivalent7
Equivalent design and functioning to HandiHaler®8
But...Costs 42% less.2,3
Tiogiva is similar to Braltus®
Same active substance5,9
Same 10 mcg delivered dose5,9
Has the same inhalation technique10
But...Costs 25% less.2,3
No need for patients to change inhaler technique when switching from another tiotropium capsule inhaler.1,10-13
91% of HandiHaler® users were able to use the Tiogiva inhaler device correctly on their first attempt8
*UK usability study involving 10 HandiHaler® users and 11 healthy volunteers with no inhaler experience. Participants were asked to use the Tiogiva device after reading the instructions for use.8
Clear capsules help patients see immediately when a full dose has been taken.5
The recommended dosage for Tiogiva is one capsule, once-daily, at the same time of day5
As with Spiriva® and Braltus®, patients are advised to take two inhalations in order to empty the capsule completely1,11,12
Tiogiva can be prescribed with an inhaler every month, or the inhaler pack on month 1 followed by repeat prescriptions of capsules for up to 5 more months.5
The second option creates opportunities to review inhaler technique every 6 months and helps reduce plastic waste5
Reducing the carbon footprint is a NHS priority.14
Tiogiva is a bioequivalent brand, no extra environmental impact is expected vs. Spiriva®7
Tiogiva helps reduce inhaler waste vs.inhalers like Braltus® and Acopair®1,12-14
Please note that Tiogiva capsules should only be inhaled using the Tiogiva inhaler and should not be inhaled using other capsule inhalers.
The following tiotropium brands are available in the UK.2,3
The table below does not necessarily represent therapeutic or bioequivalence between products.
Adapted from BNF. July 2023, and Data on file TIO/2023/08/001. August 2023.2,3
In the year leading up to March 2023 the NHS spent over £57.5 million on tiotropium capsule inhalers.2
Using Tiogiva exclusively could have reduced this by £18 million.2
Glenmark can provide financial savings estimates for your local health economy, as well as formulary information to help save you time. You can also access our Respiratory Implementation Portal, which can help you plan and implement formulary decisions, saving you time and budget.
Switching to Tiogiva could help you save significantly on your drugs budget – a Primary Care Organisation spending £846,469 annually on tiotropium capsule inhalers could have saved over £268,420 in the year to March 2023.2
If you're a member of a Medicines Management team and would like to arrange a meeting, please click here.
By dispensing Tiogiva against open tiotropium 18 mcg prescriptions, your pharmacy makes over £14 for each pack vs. Drug Tariff.3
To help you bring Tiogiva to your pharmacy, we’ve developed a series of helpful printed materials for your patients and guidance for your team:
Pharmacy guide to Tiogiva
Tear-off patient leaflets explaining how to use Tiogiva that you can put inside prescription bags
Stickers to put on prescription bags, helping staff to identify when Tiogiva has been dispensed and reminding them to discuss it with patients
Handy guide to help your team use the above, dispense Tiogiva and answer any questions patients might have
Order your support pack and materials here.
We have recently updated the design of the Tiogiva packaging, so there are two different cartons available in the UK; this won’t affect the medicine or device received.
When you prescribe Tiogiva by brand, your patients have access to clear information and support to ensure they take their medication correctly.
We offer:
Tiogiva devices with capsule placebos for practices
A dedicated Tiogiva patient website containing information and support for patients who have been prescribed Tiogiva, with guidance on how to use their inhaler and FAQs
Tear-off pads with information about Tiogiva for patients
To request support materials, click here.
You can use this video to facilitate Tiogiva device training with your patients. The video can be accessed directly by patients prescribed Tiogiva on the patient website.
You can use this video to accompany the video on how to use Tiogiva. They both can be accessed directly by patients prescribed Tiogiva on the patient website.
Tiogiva® is a registered trademark of Glenmark Pharmaceuticals Europe Limited.
© 2023 Glenmark Pharmaceuticals Europe Ltd. All rights reserved.
Date of preparation: April 2023 PP-UK-TIO-0111 V4
PIP codes:
Tiogiva dry powder inhaler and capsules 18 mcg – 4178752
Tiogiva inhalation powder, hard capsules 18 mcg (30) – 4178729
Tiogiva inhalation powder, hard capsules 18 mcg (60) – 4178711
Tiogiva® is a registered trademark of Glenmark Pharmaceuticals Europe Limited.
Spiriva® HandiHaler® and Respimat® are registered trademarks of Boehringer Ingelheim International GmbH.
Braltus® is a registered trademark of Teva UK Ltd.
Acopair® is a registered trademark of Viatris Inc.
© 2023 Glenmark Pharmaceuticals Europe Ltd. All rights reserved. Date of preparation: September 2023 PP-UK-TIO-0111 V5
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to medical_information@glenmarkpharma.com
or call 0800 458 0383.
